Cardiovascular disease is the leading cause of morbidity and mortality in people with diabetes. It has therefore been a major focus of our research in the ACHORD Group.

In particular, we have been interested in the association between diabetes, various glucose lowering therapies and cardiovascular outcomes. We have also conducted intervention studies to improve the quality of care for type 2 diabetes in primary care settings, with a particular focus on improving the management of cardiovascular risk factors, such as blood pressure and lipid management.

The Vascular Intervention Program (VIP): A strategy for medication management of cardiovascular risk in people with type 2 diabetes
Metformin and Clinical Outcomes
Patients with Heart Failure ANd Type 2 Diabetes Treated with Placebo Or Metformin (PHANTOM) Pilot Study